Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $11.9 million.

  • Iovance Biotherapeutics' Share-based Compensation fell 6162.03% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 1323.39%. This contributed to the annual value of $109.6 million for FY2024, which is 7505.31% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Share-based Compensation stood at $11.9 million, which was down 6162.03% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Share-based Compensation ranged from a high of $31.0 million in Q3 2024 and a low of $11.9 million during Q3 2025
  • Moreover, its 3-year median value for Share-based Compensation was $16.7 million (2023), whereas its average is $20.2 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Share-based Compensation skyrocketed by 11513.3% in 2024, and later tumbled by 6162.03% in 2025.
  • Iovance Biotherapeutics' Share-based Compensation (Quarter) stood at $14.4 million in 2023, then surged by 115.13% to $31.0 million in 2024, then crashed by 61.58% to $11.9 million in 2025.
  • Its Share-based Compensation was $11.9 million in Q3 2025, compared to $14.9 million in Q2 2025 and $22.9 million in Q1 2025.